Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
- CYB004, a deuterated dimethyltryptamine molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 – -- Parts A and B... | May 24, 2023